A detailed history of Massachusetts Financial Services CO transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Massachusetts Financial Services CO holds 163,104 shares of FATE stock, worth $373,508. This represents 0.0% of its overall portfolio holdings.

Number of Shares
163,104
Previous 167,055 2.37%
Holding current value
$373,508
Previous $547,000 4.2%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.12 - $5.57 $12,327 - $22,007
-3,951 Reduced 2.37%
163,104 $570,000
Q2 2024

Aug 09, 2024

BUY
$3.26 - $7.08 $18,272 - $39,683
5,605 Added 3.47%
167,055 $547,000
Q1 2024

May 14, 2024

BUY
$3.54 - $8.35 $571,533 - $1.35 Million
161,450 New
161,450 $1.19 Million
Q2 2023

Aug 09, 2023

SELL
$4.76 - $6.59 $3,850 - $5,331
-809 Reduced 2.3%
34,362 $163,000
Q1 2023

May 10, 2023

BUY
$4.24 - $11.12 $149,125 - $391,101
35,171 New
35,171 $200,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.